Online first
Letter to the Editors
Published online: 2024-07-09
Switching from oral ropinirole to ropinirole transdermal patch in patients with Parkinson’s Disease: an observational study
DOI: 10.5603/pjnns.99328
Pubmed: 38979654
Abstract
Not available
Keywords: Parkinson’s Diseaseropinirole transdermal patchswitchinglevodopa equivalent dose
References
- Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord. 2009; 15 Suppl 4: S97–100.
- Mochizuki H, Hattori N, Hasegawa K, et al. Long-term study of ropinirole patch in Parkinson's disease patients with/without basal l-dopa. Parkinsonism Relat Disord. 2021; 83: 105–109.
- Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15): 2649–2653.
- Schade S, Mollenhauer B, Trenkwalder C. Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide. Mov Disord Clin Pract. 2020; 7(3): 343–345.
